BMS Makes The Case For A Lasting Hematology Legacy
ASH Meeting Will Highlight Key Growth Products
Executive Summary
Bristol became a major hematology player through its acquisition of Celgene and it has a multi-pronged plan for maintaining its position as generics approach for Revlimid and other key products.
You may also be interested in...
Janssen/Legend’s Cilta-Cel Consistent In Earlier Myeloma, Longer-Term Results
The partners reported initial data at ASH for their BCMA-targeting CAR-T therapy in second-line multiple myeloma that appear consistent with longer-term results and ahead of their main competitor, Bristol’s Abecma.
Yescarta, Breyanzi Offer Practice-Changing Options For Second-Line LBCL
Data at ASH show CAR-T therapies may replace standard of care in an earlier line of large B-cell lymphoma with similar response rates and event-free survival for Kite’s established Yescarta and Bristol’s newer Breyanzi.
Earlier R&D Programs, Maturing Candidates Emerge From Bristol’s Pipeline
BMS is advancing a growing Phase I and II R&D pipeline, including a Factor XIa inhibitor with lower bleeding risk than current anticoagulants, as well as other internal and external research programs.